Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ 991,461
▲ 111% vs 2024
Profit
Caution€ -2.1 million
▲ 7% vs 2024
Debts
Low€ 519,996
▲ 10% vs 2024
Santero Therapeutics from Charleroi, company number BE0765790155, closed financial year 2025 with a result of € -2.1 million after tax. For that financial year Santero Therapeutics recorded a gross margin of € 991,461 and equity of € 3.6 million. Compared with financial year 2024, the result moved from € -2.3 million to € -2.1 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
What happened at Santero Therapeutics?
What happened at Santero Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Albert Palomer Benet stepped down as director. NBB
- Gokhan Batur stepped down as director. NBB
- François Fontaine stepped down as director. NBB
- SPARAXIS stepped down as director. NBB
- Cédric Govaerts stepped down as director. NBB
- Newton Biocapital II stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.1 million. Source: NBB ↗
- Abel Garcia Pino stepped down as director. NBB
In short
From € 174,979 loss in 2021 to € 2.1 million loss in 2025.
Paid € 688 in corporate taxes since 2021.
On average € 83,300 of value added per employee in 2025.
A new publication or filing at Santero Therapeutics? We notify you, reason included.
Follow Santero TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
François Fontaine
Director
since 2023 · until 2028
Director · represented by Christine Franssen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2023 · until 2028
Albert Palomer Benet
Director
since 2024 · until 2029
Cédric Govaerts
Managing director
since 2023 · until 2028
Abel Garcia Pino
Director
since 2023 · until 2025
Director · represented by TOMOKO ASAOKA
since 2024 · until 2028
Gokhan Batur
Director
since 2024 · until 2029
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Triomflaan Accès 2 box 206/2
1050 Elsene
Active since 1 December 2021
Rue Granbonpré 11
1435 Mont-Saint-Guibert
Active since 1 September 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
ImmunXperts
€ 393,338 gross margin · 2024
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
Details
- Company number
- 0765.790.155
- VAT number
- BE 0765.790.155
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- Santero Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 March 2021
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied